From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma

被引：23

作者：

Anker, Jonathan ^{[1
]}

Miller, Justin ^{[2
]}

Taylor, Nicole ^{[2
]}

Kyprianou, Natasha ^{[3
,4
,5
]}

Tsao, Che-Kai ^{[2
,3
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Internal Med, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Pathol & Mol & Cell Based Med, New York, NY 10029 USA

[5] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA

来源：

CELLS | 2021年 / 10卷 / 11期

关键词：

renal cell carcinoma; tumor microenvironment; immunology; immunotherapy; REGULATORY T-CELLS; PHASE I/II TRIAL; PATIENTS PTS; CHECKPOINT INHIBITORS; ADJUVANT SUNITINIB; SUPPRESSOR-CELLS; 1ST-LINE THERAPY; PROGNOSTIC VALUE; CTLA-4; BLOCKADE; DOSE-ESCALATION;

D O I：

10.3390/cells10113231

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Immunotherapy has revolutionized the treatment landscape for many cancer types. The treatment for renal cell carcinoma (RCC) has especially evolved in recent years, from cytokine-based immunotherapies to immune checkpoint inhibitors. Although clinical benefit from immunotherapy is limited to a subset of patients, many combination-based approaches have led to improved outcomes. The success of such approaches is a direct result of the tumor immunology knowledge accrued regarding the RCC microenvironment, which, while highly immunogenic, demonstrates many unique characteristics. Ongoing translational work has elucidated some of the mechanisms of response, as well as primary and secondary resistance, to immunotherapy. Here, we provide a comprehensive review of the RCC immunophenotype with a specific focus on how preclinical and clinical data are shaping the future of immunotherapy.

引用

页数：31

共 213 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results [J].

Amin, Asim ;

Dudek, Arkadiusz Z. ;

Logan, Theodore F. ;

Lance, Raymond S. ;

Holzbeierlein, Jeffrey M. ;

Knox, Jennifer J. ;

Master, Viraj A. ;

Pal, Sumanta K. ;

Miller, Wilson H., Jr. ;

Karsh, Lawrence I. ;

Tcherepanova, Irina Y. ;

DeBenedette, Mark A. ;

Williams, W. Lee ;

Plessinger, Douglas C. ;

Nicolette, Charles A. ;

Figlin, Robert A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3

[3] Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors [J].

Apolo, Andrea B. ;

Nadal, Rosa ;

Girardi, Daniel M. ;

Niglio, Scot A. ;

Ley, Lisa ;

Cordes, Lisa M. ;

Steinberg, Seth M. ;

Sierra Ortiz, Olena ;

Cadena, Jacqueline ;

Diaz, Carlos ;

Mallek, Marissa ;

Davarpanah, Nicole N. ;

Costello, Rene ;

Trepel, Jane B. ;

Lee, Min-Jung ;

Merino, Maria J. ;

Bagheri, Mohammad Hadi ;

Monk, Paul ;

Figg, William D. ;

Gulley, James L. ;

Agarwal, Piyush K. ;

Valera, Vladimir ;

Chalfin, Heather J. ;

Jones, Jennifer ;

Streicher, Howard ;

Wright, John J. ;

Ning, Yangmin M. ;

Parnes, Howard L. ;

Dahut, William L. ;

Bottaro, Donald P. ;

Lara, Primo N., Jr. ;

Saraiya, Biren ;

Pal, Sumanta K. ;

Stein, Mark N. ;

Mortazavi, Amir .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) :3672-+

[4] The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma [J].

Ascierto, Maria Libera ;

McMiller, Tracee L. ;

Berger, Alan E. ;

Danilova, Ludmila ;

Anders, Robert A. ;

Netto, George J. ;

Xu, Haiying ;

Pritchard, Theresa S. ;

Fan, Jinshui ;

Cheadle, Chris ;

Cope, Leslie ;

Drake, Charles G. ;

Pardoll, Drew M. ;

Taube, Janis M. ;

Topalian, Suzanne L. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (09) :726-733

[5]

Atkins MB, 2020, J CLIN ONCOL, V38

[6] Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC) [J].

Becht, Etienne ;

Giraldo, Nicolas A. ;

Beuselinck, Benoit ;

Job, Sylvie ;

Marisa, Laetitia ;

Vano, Yann ;

Oudard, Stephane ;

Zucman-Rossi, Jessica ;

Laurent-Puig, Pierre ;

Sautes-Fridman, Catherine ;

de Reynies, Aurelien ;

Fridman, Wolf Herman .

ONCOIMMUNOLOGY, 2015, 4 (12)

[7] Metabolic barriers to immunotherapy in renal cell carcinoma. [J].

Beckermann, Katy ;

Siska, Peter ;

Mason, Frank ;

Rathmell, Kimryn ;

Rathmell, Jeffrey C. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8]

Bex A, 2020, J CLIN ONCOL, V38

[9] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma [J].

Bi, Kevin ;

He, Meng Xiao ;

Bakouny, Ziad ;

Kanodia, Abhay ;

Napolitano, Sara ;

Wu, Jingyi ;

Grimaldi, Grace ;

Braun, David A. ;

Cuoco, Michael S. ;

Mayorga, Angie ;

DelloStritto, Laura ;

Bouchard, Gabrielle ;

Steinharter, John ;

Tewari, Alok K. ;

Vokes, Natalie, I ;

Shannon, Erin ;

Sun, Maxine ;

Park, Jihye ;

Chang, Steven L. ;

McGregor, Bradley A. ;

Haq, Rizwan ;

Denize, Thomas ;

Signoretti, Sabina ;

Guerriero, Jennifer L. ;

Vigneau, Sebastien ;

Rozenblatt-Rosen, Orit ;

Rotem, Asaf ;

Regev, Aviv ;

Choueiri, Toni K. ;

Van Allen, Eliezer M. .

CANCER CELL, 2021, 39 (05) :649-+

[10] The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation [J].

Bianchi, Cristina ;

Meregalli, Chiara ;

Bombelli, Silvia ;

Di Stefano, Vitalba ;

Salerno, Francesco ;

Torsello, Barbara ;

De Marco, Sofia ;

Bovo, Giorgio ;

Cifola, Ingrid ;

Mangano, Eleonora ;

Battaglia, Cristina ;

Strada, Guido ;

Lucarelli, Giuseppe ;

Weiss, Robert H. ;

Perego, Roberto A. .

ONCOTARGET, 2017, 8 (69) :113502-113515

← 1 2 3 4 5 6 7 8 9 10 →